Relic Technologies Limited has disclosed another substantial acquisition of shares by its promoter group under SEBI regulations. The company filed the latest disclosure on March 17, 2026, detailing a recent share purchase by promoter Alisha Kunal Gandhi.

Latest Share Acquisition Details

Alisha Kunal Gandhi acquired 2,000 equity shares of Relic Technologies through open market purchase on March 16, 2026. The acquisition represents 0.04% of the company's total share capital, further strengthening the promoter group's stake in the company.

Promoter Group Structure

The promoter group consists of Alisha Kunal Gandhi as the acquirer and three persons acting in concert:

• Kunal Narendra Gandhi
• ENAI Trading and Investment Private Limited
• Nehal Narendra Gandhi

The disclosed shareholding percentages represent the aggregate holding of all promoters and persons acting in concert, demonstrating continued consolidation of ownership within the promoter group.

Company Share Capital

Relic Technologies' equity share capital remains unchanged at Rs. 5,59,11,640, divided into 55,91,164 equity shares of Rs. 10 each. The company's shares are listed on BSE Limited under scrip code 511712.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The filing demonstrates the promoter group's continued commitment to maintaining transparency in share transactions and adhering to regulatory requirements for substantial acquisitions. This marks the second recent acquisition by the promoter group, indicating sustained confidence in the company's prospects.

Relic Technologies Limited (BSE: 511712) has announced its unaudited financial results for the quarter ended September 30, 2025, revealing a mixed performance across its standalone and consolidated operations. The company also disclosed plans to voluntarily strike off its non-operative subsidiary, Relic Pharma Limited.

Financial Highlights

Standalone Performance

• Net profit for Q2 stood at Rs 17.52 crore, up from Rs 9.75 crore in the previous quarter.
• Total income for the quarter was Rs 34.81 crore.
• For the half-year, net profit reached Rs 19.19 crore.

Consolidated Performance

• The company reported a consolidated net loss of Rs 2.30 crore for Q2.
• Half-yearly consolidated operations showed a net loss of Rs 353.39 crore.

Key Financial Metrics

Subsidiary Strike-Off Plans

The Board of Directors has approved the voluntary striking off of its non-operative subsidiary, Relic Pharma Limited. Key points regarding this decision include:

• Relic Pharma Limited had nil turnover and a negligible net worth of Rs 1.019 lakh.
• The strike-off process is expected to be completed by March 31, 2026, subject to regulatory approval.
• This move aligns with the company's strategy to streamline its operations and focus on core business activities.

Capital Structure Update

Relic Technologies' paid-up equity share capital increased to Rs 515 crore from Rs 360 crore, indicating a significant capital infusion or possible bonus issue.

Audit Review

The financial results were reviewed by the company's auditors, D. Kothary & Co., who provided an unmodified opinion, lending credibility to the reported figures.

Investor Considerations

While the standalone results show improvement, the consolidated performance indicates challenges within the group. Investors should note the following:

1. The stark difference between standalone and consolidated results suggests varying performances across the company's subsidiaries.
2. The decision to strike off Relic Pharma Limited may impact future consolidated results by eliminating a non-performing entity.
3. The increase in paid-up capital could provide the company with additional resources for growth or debt reduction.

As Relic Technologies navigates through these mixed results and structural changes, stakeholders will be watching closely to see how these developments translate into long-term value creation and improved financial health across the group.